חודש המודעות לסרטן השד בחסות Novartis Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor–positive, HER2-negative breast cancer NEJM
חודש המודעות לסרטן השד בחסות Novartis Pooled Safety Analysis of First-Line Ribociclib Plus Endocrine Therapy in HR+/HER2− Advanced Breast Cancer Journal of Clinical Oncology
חודש המודעות לסרטן השד בחסות Novartis Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor– positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment na¨ıve or had received up to one line of prior endocrine therapy in the advanced setting. Journal of Clinical Oncology
תגובות אחרונות